NVSR, OPSY, MRNJ, GOHG, SNRY, FNXC, ANDS, EVRN, AMNE, SKVI, EREI Daily Market Movers Digest Midday Report for Friday, July 31st from OTCPicks.com
Our Stocks to Watch today include NavStar Technologies Inc. (OTC: NVSR), Optical Systems Inc. (OTC: OPSY), Metatron Inc. (OTC: MRNJ), Alpha1 Security Inc. (OTCBB: GOHG), Solar Energy Initiatives Inc. (OTCBB: SNRY), Fonix Corp. (OTCBB: FNXC), Anadys Pharmaceuticals Inc. (Nasdaq: ANDS), Everock Inc. (OTC: EVRN), American Green Group Inc. (OTC: AMNE), Skinvisible Inc. (OTCBB: SKVI) and Worldwide Food Services Inc. (OTC: EREI).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
"Up 4.08% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
July 30 - Anything Trucker, Inc Signs LOI to Become US Marketing Arm for Sales and Distribution of NavStar Technologies, Inc. Products
Anything Brands Online’s (OTC: ANYT) Anything Trucker unit announced the signing of a LOI to provide sales and distribution of NavStar Technologies' product lineup for the
Anything Trucker and Anything Brands Online’s myFreightWorld division (www.3plinabox.net) will leverage their existing sales force to provide equipment, software and related services to trucking and other commercial transportation companies in the
Tim Norton, President, Anything Trucker, stated, "We are pleased that NavStar has placed its confidence in our organization for the promotion and sale of its product line. I feel we have a partner in NavStar that shares our passion to provide new products and services that will change the way commercial vehicles communicate that will ultimately lead to increased efficiencies and profitable operations."
"I am convinced that when NavStar and Anything Trucker get focused on making the US trucking industry more productive and efficient, you will see some new software and applications that have not been available until now," said N. Douglas Pritt, Chairman & CEO NavStar Technologies, Inc. "Something as simple as immediate confirmation of delivery can improve cash flow for a trucking company by several days and sometimes as much as a week. There are dozens of applications we can develop immediately. With more than 30 million trucks in the
ABOUT ANYTHING BRANDS ONLINE, INC.
Anything Brands (www.anythingbrandsonline.com) markets and sells products and services that improve the level of transportation efficiency and safety of its commercial and recreational customers. Their Tradesman Tool division (www.tradesmantool.com) serves automotive, construction, industrial tools, and auto body supplies. The myFreightWorld division is a business outsourcing company that sells technology, services, and wholesale truck, rail, and airfreight capacity to the logistics manager industry that accounts for over $200 billion of the $650 billion transportation industry spend. Technology services and products are offered via the web or are accessible through web service applications and are provided primarily through private label arrangements.
OPTICAL SYSTEMS INCORPORATED (OTC: OPSY)
Detailed Quote: http://www.otcpicks.com/quotes/OPSY.php
Company Profile: http://www.otcpicks.com/optical-systems/optical-systems.htm
Optical Systems, Inc., through its operating subsidiary, Automotive Software Designers, Inc., develops technology and services for the automotive retail industry designed to maximize productivity and increase profits at auto dealerships. ASDI's flagship technology solution, Save-a-Deal, is a turnkey customer relationship management (CRM) tool for auto dealerships. Our business development center (BDC) provides a variety of services designed to help auto dealerships drive traffic to their showroom or Web site, retain customers and generate new streams of revenue.
OPSY News:
July 29 - Optical Systems, Inc. Launches Cutting-Edge GPS System for Auto Dealerships More Robust Than LoJack
Optical Systems, Inc. (OTC: OPSY), a leading provider of software and services for the automotive retail industry today announced the launch of Save-a-Car GPS, a cost-effective, global positioning system for auto dealerships to monitor and track inventory.
"Save-a-Car is a low-cost, robust tracking system that represents a huge market opportunity for our company," said B.J. Grisaffi, CEO of Optical Systems, Inc. "There has been a lot of enthusiasm, excitement and positive feedback about Save-a-Car from dealerships. In today's market, dealers need scalable products that have a solid return on investment. Save-a-Car is a state-of-the art GPS system that helps dealers track inventory and maximize profit potential like never before. This small, covert system can be sold to the customer as a theft and tracking device that is much more robust than LoJack and available with no monthly fee. Our system works nationwide, where LoJack only works in certain areas," said Grisaffi.
In addition to offering superior tracking capabilities, Save-a-Car also allows drivers to save up to 35 percent on their insurance premium when installed.
Growing usage in automotive and consumer applications is propelling the mobile location technologies market, which is forecasted to grow at a CAGR of more than 20 percent to cross US$ 75 Billion by 2013, says "World GPS Market Forecast to 2013," a new market research report by RNCOS.
"We already have more than 30 dealerships enrolled in our Save-a-Deal and
Save-a-Car is currently available through the Company's operating subsidiary, Automotive Software Designers.
METATRON INCORPORATED (OTC: MRNJ)
Detailed Quote: http://www.otcpicks.com/quotes/MRNJ.php
Company Profile: http://www.otcpicks.com/metatron-inc.htm
Metatron Inc. is a diversified internet holding company with a mission to harness the power of today's online and wireless consumer interactivity to make daily life easier, more productive and more entertaining for people all over the world. Our objective is to acquire high potential internet properties and to monetize those operations based on our extensive experience and knowledge of Web 2.0, the second generation of web development and design that facilitates nearly-universal communication, secure information sharing, interoperability, and collaboration on the web.
MRNJ News:
July 30 - Valencia Research Group Initiates Coverage on Metatron Inc. With a Speculative Buy Rating
Analyst Assigns Fair Market Value at $1.11 per Share
Metatron Inc. (OTC: MRNJ), a diversified internet holding company, announced that CA-based boutique equity research firm, Valencia Research Group, has initiated coverage on the Company with a "Speculative Buy" rating and a fair-market-valuation of $1.11 per share.
Jasmine Breitbach, CFA, MBA, Senior Analyst with
Ms. Breitbach continued, "Based on the growth potential of Metatron's suite of product and services, and the valuation of related comparables, we believe the stock is undervalued and are assigning a fair market value the stock at $1.11 a share."
A full copy of the report is available under the "Research" tab at www.pinksheets.com/pink/quote/quote.jsp?symbol=MRNJ. Ms. Breitbach can be reached via email at jbreitbach22@yahoo.com.
ALPHA 1 SECURITY INCORPORATED (OTCBB: GOHG)
Detailed Quote: http://www.otcpicks.com/quotes/GOHG.php
Company Profile: http://www.otcpicks.com/global-holdings/global-holdings.htm
Alpha1 provides Internet based (IP) data security services as well as develops and markets software and microprocessor-based products. Alpha1's primary data security products use an advanced form of computer security technology referred to as public key infrastructure (PKI) which enables Alpha1's products to integrate. Alpha1 is an approved NSA C-2 classified contractor.
GOHG News:
July 30 - Alpha1 Security Gets Contract, in Principle, for $75 Million Over Five Years
Alpha1 Security Inc. has agreed in principle with George Karam, Chairman of Karamco Inc., to provide secure communications to the government of
Alpha1 provides Internet based (IP) data security services as well as develops and markets software and microprocessor-based products. Alpha1's primary data security products use an advanced form of computer security technology referred to as public key infrastructure (PKI) which enables Alpha1's products to integrate. Alpha1 is an approved NSA C-2 classified contractor.
SOLAR ENERGY INITIATIVES INCORPORATED (OTC BB: SNRY)
Detailed Quote: http://www.otcpicks.com/quotes/SNRY.php
Company Profile: http://www.otcpicks.com/solar-energy-initiatives.htm
Solar Energy Initiatives, Inc. (www.SolarEnergy.com) is executing its “RENEW THE NATION” campaign, intended to promote job growth nationwide via an aggressive grass roots effort. The main focus of RENEW THE NATION will be working with companies in the construction industry and related trades affected by the economic downturn to re-train and re-deploy their workforce, allowing this important national asset to meet the needs of the Solar Energy industry, the fastest growing industry in the world. We are executing on a three-pronged approach to achieve our plan. This includes: continuing development of one of the fastest growing dealer networks in the U.S. that sells and installs solar solutions to homeowners and commercial customers; placing solar systems on large commercial buildings and selling the energy output to the owner/occupant(s); and becoming a developer of solar parks bringing together landowners, utilities and our corporate resources to build large photovoltaic installations. The Company’s dealer network of solar energy installers has access to Suntech Power Holdings Co., Ltd. (NYSE: STP), BP Solar (NYSE: BP) and GE Solar (NYSE: GE) equipment via its distribution agreements. While Solar Energy Initiatives is not a solar franchise, and the Company does not compete directly with industry giants such as First Solar (Nasdaq: FSLR), Kyocera (NYSE: KYO) or Sanyo (OTC: SANYY), as a system integrator, it provides exciting and practical solutions to businesses and individuals worldwide that understand the value of solar power.
SNRY News:
July 29 - Solar Energy Initiatives Announces Securing Land to Build a 300 Megawatt Solar Park in
* The Project Is Estimated to Generate Approximately $750 Million
* The
Solar Energy Initiatives, Inc. (OTCBB: SNRY), executing on a grass roots campaign, “RENEW THE NATION”, to help redeploy a portion of the U.S. work force and focus on reducing the world’s dependence on fossil fuels by selling solar thermal and photovoltaic (PV) technologies, today announced that the Company signed a contract securing land for the design, construction and operation of a solar park in west Texas. A Limited Liability Company will be formed to own, finance and operate the solar park. Solar Energy Initiatives will sell the solar panels and balance of system to the LLC, generating as much as $750 million in revenue within a 6 year time period. During the first year of development, the project will generate over $100 million in sales. The revenue approximation is solely based on the sale of the solar panels and does not account for the sale of generated electricity.
Construction of the 300 megawatt system represents the largest non-utility owned solar park to be created. Preliminary work, including zoning, permitting, EPA approvals and other activities will begin immediately with construction set to begin in the next 18 months. The project will be constructed in various increments over the six year time frame. At full capacity, the solar park could generate enough green renewable energy to displace approximately 700,000 metric tons of carbon emissions, annually, that would have otherwise been produced by non-renewable power generation. The project could produce enough energy to provide power to approximately 60,000 homes.
“Solar Energy Initiatives is thrilled to have secured such a monumental contract,” stated, David Fann, Chief Executive Officer of Solar Energy Initiatives. “The size and scope of this venture represents a significant milestone in establishing the Company as a true market leader within the rapidly expanding solar deployment sector. It is an incredible testament to our management team and Board of Directors that we have been successful in securing the contract to build the largest non-utility owned solar park.”
Mr. Fann continued, “As we continue to attract additional funding for these projects from our partners we will bid on new projects that make strong economic sense for our Company. The deployment of these large scale projects will enhance our ability to negotiate panel prices with solar panel providers which will enhance our overall margins and drive our profitability. Management believes that the signing of the solar park contracts will assist us in working with additional municipalities and land owners to obtain additional contracts, increase our earnings and achieve our primary goal of improved shareholder value.”
FONIX CORPORATION (OTCBB: FNXC)
"Up 74.36% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FNXC.php
Fonix Corporation, based in
FNXC News:
July 30 - Fonix iSpeak 1.4 Now Available for iPhone 3.0
Fonix Speech, Inc., a wholly owned subsidiary of Fonix® Corporation (OTCBB: FNXC) specializing in embedded speech interfaces for mobile devices, handheld electronic products, video game systems and processors, today debuted Fonix iSpeak™ 1.4 for the Apple iPhone™ 3.0 operating system.
Fonix iSpeak provides voice dial by name or number with highly accurate speech recognition software (especially in noisy environments) and voice confirmation using recorded speech together with text-to-speech. Fonix iSpeak allows for nearly hands-free use, no buttons to hold while speaking, and quick integration of names and numbers from your contact list.
“While the iPhone 3GS recently introduced its own voice-recognition function, Fonix iSpeak works with any model of the iPhone,” said Fonix CEO Roger Dudley. “iSpeak was designed to manage more contacts and deliver a higher level of professional quality voice control than other technologies on the market.”
Fonix iSpeak 1.4 includes the following new features and functions:
*Highly accurate when used in a vehicle. iSpeak is more accurate than the Voice Control software in the 3GS.
*Easily manages expanded number of contacts.
*Delivers professional quality voice prompts, improving the output sound.
*Compatible with Apple’s new and improved iPhone 3.0 audio functionality.
*After updating to the new iPhone 3.0 OS, current iSpeak users receive a free update to iSpeak 1.4 (the Voice Control software on the new iPhone 3GS is not available for 2G and 3G phones).
*iPhone 2G, 3G and 3GS users wanting the benefits of Fonix iSpeak may purchase iSpeak 1.4 through the Apple AppStore.
Fonix iSpeak runs on the device, eliminating time delays by processing the speech signal through an off-site server. The program does not record names and numbers on a public server, nor requires holding buttons on the iPhone when in use.
Fonix iSpeak can be purchased for US$2.99 through the Apple iTunes App Store™ in the Productivity and/or Utilities category (www.apple.com). Fonix iSpeak is available for 2G, 3G and 3GS models with iPhone OS 3.0. For more information go to www.fonixspeech.com or call (801) 553-6600 and say “iSpeak support” or “sales” for demos, availability and pricing.
ANADYS PHARMACEUTICALS INCORPORATED (NASDAQ: ANDS)
"Up 77.78% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ANDS.php
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
ANDS News:
July 30 - Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Cash Reserves Augmented with Recently Completed Financing Expected to Fund Operations into 2011
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its financial results and program highlights for the second quarter ended June 30, 2009.
"With our enhanced cash position, reduced cost structure and Phase II protocol allowance from the FDA, we are well positioned to continue advancing the development of ANA598 as a treatment for chronic hepatitis C," said Steve Worland, Ph.D., President and CEO of Anadys. "ANA598 has demonstrated potent antiviral activity and good tolerability in Phase I, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens. The upcoming Phase II trial has several important elements, including twelve weeks of ANA598 combination treatment and a randomized exploration of shortening the overall duration of HCV therapy in conjunction with ANA598 treatment. We look forward to receiving the first data from this trial by year-end 2009 and additional data in the first half of 2010."
Financial Results
As of June 30, 2009, the Company's cash, cash equivalents and securities available-for-sale totaled $30.6 million compared to $27.9 million as of December 31, 2008. The increase in cash, cash equivalents and securities available-for-sale is the result of proceeds received from a "registered direct" offering of common stock and warrants in early June 2009, partially offset by the year-to-date cash utilization.
Research and development expenses were $4.6 million for the second quarter of 2009, compared to $5.5 million for the second quarter of 2008. The $0.9 million decrease was primarily attributable to a $1.3 million decrease in ANA773 development costs partially offset by $0.5 million in severance costs recorded in conjunction with the strategic restructuring initiated in June 2009. ANA773 development costs during the second quarter of 2009 were primarily driven by the ongoing Phase I clinical trial for the treatment of hepatitis C. During the second quarter of 2008, ANA773 development costs were primarily driven by the now completed 13-week GLP animal toxicology studies and the Phase I oncology clinical trial. The ANA598 development costs during the second quarter of 2009 were primarily associated with the 14-day healthy volunteer study and the ongoing long-term chronic toxicology studies which were initiated in September 2008.
General and administrative expenses were $2.5 million for the second quarter of 2009, compared to $2.0 million for the second quarter of 2008. The $0.5 million increase primarily resulted from severance costs recorded in conjunction with the strategic restructuring initiated in June 2009.
Operating expenses were $7.2 million for the second quarter of 2009, compared to $7.5 million for the second quarter of 2008. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $1.1 million and $0.7 million for the second quarter of 2009 and 2008, respectively.
The net loss was $6.5 million for the second quarter of 2009, compared to a net loss of $7.1 million for the second quarter of 2008. Included in the net loss for the second quarter of 2009 is a $0.4 million gain resulting from a reduction between issuance and June 30, 2009 in the liability associated with common stock warrants issued in conjunction with the "registered direct" financing. Basic and diluted net loss per common share was $0.21 in the second quarter of 2009, compared to $0.25 in the second quarter of 2008. Non-cash share-based expense resulted in a $0.03 and $0.02 increase in basic and diluted net loss per share for the second quarter of 2009 and 2008, respectively.
For the six months ended June 30, 2009, Anadys reported a net loss of $15.3 million, compared to $14.5 million for the same period last year. Basic and diluted net loss per common share was $0.51 for the six months ended June 30, 2009 and 2008.
Operational Highlights
* Closed Registered Direct Financing. In early June, Anadys closed a "registered direct" offering through the sale of units to institutional investors, with each unit consisting of one share of common stock and a warrant to purchase 0.35 of a share of common stock. $17.5 million in gross proceeds were raised, with net proceeds of approximately $16.0 million, after deducting placement agent fees and estimated offering expenses. Proceeds from the transaction are being used to further the development of ANA598, as well as for other general corporate purposes.
* Future Operations to Focus on Development of ANA598. In June, Anadys initiated a strategic restructuring to focus its operations on the continued development of ANA598, in particular a Phase II study in combination with pegylated interferon-alpha and ribavirin. The restructuring included a reduction in Anadys' workforce expected to generate annual savings of $4 to $5 million, while retaining the clinical development infrastructure required to conduct the Phase II study of ANA598, key capabilities directed toward pharmaceutical development and next generation non-nucleosides, and a streamlined administrative staff. Also included in the restructuring is an expected reduction in annual facility expense of approximately $1.8M associated with our completed move to a smaller facility.
Development Program Highlights
ANA598 is the Company's non-nucleoside HCV polymerase inhibitor.
* Finalization of ANA598 Phase II Protocol. Anadys has finalized its protocol and received FDA clearance for the Phase II study of ANA598 in combination with pegylated interferon-alpha and ribavirin for the treatment of chronic hepatitis C. In the Phase II study, naive genotype 1 patients will receive ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) (a current standard of care, or SOC) for 12 weeks at dose levels of 200 mg or 400 mg twice daily (bid), each with a loading dose of 800 mg bid on day one. After week 12, patients will continue to receive SOC alone. Patients who have undetectable levels of virus at weeks 4 and 12 will be randomized to stop all treatment at either week 24 or 48. The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (complete Early Virological Response or cEVR). Response at week 4 will also be assessed to provide the rate of Rapid Virological Response, or RVR. Patients will be followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR. Ninety patients are planned to be enrolled in this study - thirty patients receiving ANA598 and fifteen receiving placebo at each dose level. The study will be conducted at a number of clinical sites in the
* Reported Potent Antiviral Activity/Good Tolerability in HCV at EASL. In April 2009, data demonstrating potent antiviral activity and good tolerability of ANA598 as a single agent at all dose levels in a Phase Ib study in HCV patients were reported at the EASL conference. The median viral load reduction over three days ranged from 2.4 to 2.9 log10 in the three dose groups studied. No patient at any dose level showed evidence of viral rebound while on ANA598 and there were no serious adverse events.
* Reported 14-day Healthy Volunteer Study Results. In April 2009, Anadys reported results from a 14-day study of ANA598 in healthy volunteers. ANA598 was generally well-tolerated in all cohorts in the study with no serious adverse events. Three instances of mild-to-moderate rash were observed at the higher dose levels. Pharmacokinetic results from this trial confirmed the plasma half-life of ANA598 of approximately 24 hours, and demonstrated that steady-state levels of ANA598 in plasma are reached after six to seven days of dosing.
* Dosing Completed in Long-Term Chronic Toxicology Studies. The dosing period is completed in two long-term, chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys). At the 13-week interim, the toxicology profile of ANA598 in both species was very favorable. While 39-week data from the monkey study is not yet available, a preliminary assessment of the results from the 26-week study in rats indicates a similar profile to that seen in rats at 13 weeks, in which the only adverse finding was a marginal decrease in the rate of weight gain in females at 1000 mg/kg, the highest dose tested. Complete results from both studies are expected at the end of the third quarter 2009.
ANA773 is the Company's oral inducer of endogenous interferons that acts via the toll like receptor 7 (TLR7) pathway.
* Phase I Clinical Trial in HCV. Nine patients have completed dosing at 2000 mg in the Company's trial of ANA773 in HCV patients, and the final patient is currently being dosed. During the second quarter the Company reported evidence of viral load reduction in a majority of patients who received ANA773 at 1600 mg. Anadys expects to present further results from this study later this year and intends to explore
* Reported PK/PD Data for ANA773 in HCV at EASL. In April 2009, the pharmacokinetic (PK) and pharmacodynamic (PD) data from the healthy volunteer portion of the Phase I clinical trial of ANA773 in HCV were reported at the EASL conference. ANA773 was generally well tolerated with no serious adverse events. Plasma drug levels were proportional to dose, and there was a dose-dependent induction of well-recognized interferon dependent biomarkers.
* Phase I Clinical Trial in Oncology. In order to focus its resources on ANA598, Anadys recently elected to stop enrollment of new patients in the ongoing Phase I oncology trial of ANA773. Anadys plans for currently enrolled patients to continue to receive ANA773 until disease progression is observed and to conclude the trial once all patients reach this point.
EVEROCK INCORPORATED (OTC: EVRN)
"Up 3.79% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EVRN.php
Everock, Inc. produces a line of all-natural natural gourmet vegetable dips and sandwich spreads marketed under the Nature's Peak brand. Both VeggieDip and VeggieSpread are 100% all-natural, vegetarian, Kosher and gluten-free, contain no preservatives, artificial ingredients, trans-fats, or sugars. And each product currently comes in six flavors each, including novel delicious flavor combinations. Nature's Peak products may be found in natural food stores, specialty groceries as well as in regional and national grocery chains. Our products are also served by restaurants, delis and other food service providers across
EVRN News:
July 30 - Tree of Life, a Leading National Specialty Food Distributor Servicing over 10,000 Stores, Agrees to Represent Nature's Peak All-Natural Products
A national distribution agreement for Nature's Peak all-natural food products now exists between Everock, Inc (Nature's Peak) and Florida-based specialty food distributor Tree of Life, Inc.
Everock, Inc. (OTC: EVRN) announced it has forged a national distribution agreement for its Nature's Peak product line with St. Augustine, Florida based national specialty food distributor Tree of Life, Inc.
Tree of Life, Inc. is a leading marketer and distributor of organic, natural and specialty foods, serving customers throughout the
Eleven-hundred Tree of Life field sales associates serve more than 10,000 retailers including, health food stores, gourmet shops, major supermarket chains, and mass-market merchants.
"Tree of Life has a long and successful history of meeting the needs of the growing numbers of people who choose a health-conscious lifestyle," said Paul Wilkinson, CEO of Everock/Nature's Peak. "And that's why the Nature's Peak all-natural VeggieDip and VeggieSpread products fit so well with the Tree of Life product mix."
"We welcome this exceptional opportunity offered by Tree of Life. We hope to introduce Nature's Peak products as an exciting alternative to mayonnaise to a wide range of consumers. Plus, we'll also have a chance to be on shelves at a diverse group of new retailers; from specialty groceries to mass marketers, like Wal-Mart."
AMERICAN GREEN GROUP INCORPORATED (OTC: AMNE)
"Up 53.85% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AMNE.php
AMNE is moving into the six billion building insulation business by becoming a cutting edge chemical sales company. The company is creating a new, wholly owned subsidiary to operate this business which will be headed by Terry Mixon, who plans on implementing this business strategy by using the web, mailing, telephone marketing, and television advertising campaign to grow our associate applicator membership to at least 5 distributor companies in each state. AMNE will begin by recruiting known successful application companies in each state then begin a web-based associate membership drive. The corporation will offer equipment, training and great pricing plus marketing support through the web program to all new associates.
AMNE News:
July 30 - AMNE and Florida Sales Company Expand Agreement to Include Infinite R
American Green Group, Inc. (OTC: AMNE) (www.americangreegroup.com) announces it has a signed a licensing deal with Ecosafe Insulation of Florida, LLC (ECOFL) to market "Infinite R," in the State of Florida. AMNE would also like to remind shareholders Friday is the shareholder of record date as issued by FINRA for the 5 for 1 forward split. In order to receive the dividend, you must be a shareholder of record on the close of that day.
AMNE has granted ECOFL licenses in 5 of Floridaorida's biggest counties to market Ecosafe Foam and felt it was a natural fit for ECOFL to market Infinite R at the same time. ECOFL has retained a local law firm to assist the company in getting the State of
ECOFL will become a manufacture of the Infinite R so it can distribute the product easily throughout the state. With the help of AMNE, they are actively seeking machinery to purchase and setup a facility.
ECOFL has ordered a Sprinter truck from AMNE which is being outfitted with spray gear for the Ecosafe Foam and is expected to be delivered by mid August. ECOFL has retained a local PR company to help launch both products after the truck arrives with a media event scheduled which will feature a demonstration of both products to help launch both products in
ABOUT INFINITE R
Infinite R controls the temperature differential across the R-value. If the temperature difference can be kept low then the heat flow across any R-value is also kept low. If the temperature difference, sometimes referred to as Delta T, equals zero then zero heat flow occurs. Using this new patented technology, zero heat flow conditions have been witnessed even when large temperature differentials existed between the two spaces.
SKINVISIBLE INCORPORATED (OTCBB: SKVI)
"Up 24.14% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SKVI.php
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare.
SKVI News:
July 31 - Invisicare Approved for Additional
Further Intellectual Property Protection Enhances Skinvisible's Value
Skinvisible, Inc. (OTCBB: SKVI), a research and development company of topical dermatology products, announced that it has been approved for a new
The Invisicare patent covers the distinct areas of: Methods of Manufacturing, Composition and Methods of Use. With this new patent Skinvisible is allowed additional protection for its Invisicare technology under the category of Topical Composition and Topical Composition Precursor. The
"This announcement strengthens Skinvisible's intellectual property protection for our proprietary formulated dermatology and consumer goods products that we have developed using Invisicare," said Mr. Terry Howlett, President and CEO of Skinvisible. "We believe this added IP strength will be one of the catalysts to further our licensing efforts not only in the
Seven patents in total have been issued to Skinvisible. This includes three patents in the
ABOUT DERMSAFE
Skinvisible's DermSafe 4% chlorhexidine gluconate hand sanitizing lotion provides a protective solution that is unique from other products on the market due to its patented technology Invisicare. Invisicare binds to the skin so that reapplication of DermSafe is only required after four hours of continuous protection. This patent-pending sanitizing hand lotion does not contain alcohol and has a proven ability to kill gram positive and gram negative bacteria and viruses including the H1N1 swine flu virus.
ABOUT INVISICARE
Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives and reduce irritation. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.
WORLDWIDE FOOD SERVICES INCORPORATED (OTC: EREI)
"Up 27.45% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EREI.php
Worldwide Food Services has established an international marketing and distribution system for food and beverage products in a global economy. The company was formerly known as Eagle Rock Enterprises, Inc.
EREI News:
July 30 - Worldwide Food Services Signs Joint Venture Agreement
Worldwide Food Services Inc. (OTC: EREI) (WWFS) has signed a Joint Venture Agreement with Rainbow Foods.
Under the terms of the Agreement, Rainbow Foods agrees to oversee all procurement of products, assembly, warehousing, packing, storage and distribution of the Emergency Food Kits for the Department of Defense and for FEMA, named in the BOA ordering agreement, for Rastelli Global and contracted exclusively to Worldwide Food Services, Inc.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com has been compensated one hundred thousand free trading shares by a third party for OPSY advertising and promotional services. OTCPicks.com has been compensated three thousand dollars by a third party (Stock Awareness Group) for MRNJ advertising and promotional services. OTCPicks.com has been compensated twenty thousand free trading shares by a non-controlling third party for GOHG advertising and promotional services. OTCPicks.com has been compensated three thousand dollars by a third party (Level Up Industries) for SNRY advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
